Hyperkalemia occurred at higher rates with finerenone than placebo, but 99% of patients completed the trials.178–180 Finerenone can be added to standard of care treatment (including a RAS inhibitor and SGLT2 inhibitor) for people with T2D and CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.